IFITM3 and acute myeloid leukemia: This finding was validated in an independent cohort54 of ex vivo drug screening in AML, where patients with high IFITM3 expression or IFNγ signaling score were less sensitive to venetoclax-based therapy (i.e. more resistant to venetoclax) (Fig. 6B).